183 related articles for article (PubMed ID: 35751778)
1. Somatostatin receptor-directed molecular imaging for therapeutic decision-making in patients with medullary thyroid carcinoma.
Serfling SE; Zhi Y; Megerle F; Fassnacht M; Buck AK; Lapa C; Werner RA
Endocrine; 2022 Oct; 78(1):169-176. PubMed ID: 35751778
[TBL] [Abstract][Full Text] [Related]
2. Somatostatin Receptor-Directed PET/CT for Therapeutic Decision-Making and Disease Control in Patients Affected With Small Cell Lung Cancer.
Serfling SE; Hartrampf PE; Zhi Y; Higuchi T; Kosmala A; Serfling J; Schirbel A; Hörning A; Buck AK; Weich A; Werner RA
Clin Nucl Med; 2023 Apr; 48(4):309-314. PubMed ID: 36754127
[TBL] [Abstract][Full Text] [Related]
3. Somatostatin receptor imaging in non-(131)I-avid metastatic differentiated thyroid carcinoma for determining the feasibility of peptide receptor radionuclide therapy with (177)Lu-DOTATATE: low fraction of patients suitable for peptide receptor radionuclide therapy and evidence of chromogranin A level-positive neuroendocrine differentiation.
Jois B; Asopa R; Basu S
Clin Nucl Med; 2014 Jun; 39(6):505-10. PubMed ID: 24662668
[TBL] [Abstract][Full Text] [Related]
4. Feasibility and therapeutic potential of the 68Ga/177Lu-DOTATATE theranostic pair in patients with metastatic medullary thyroid carcinoma.
Dadgar H; Jafari E; Ahmadzadehfar H; Rekabpour SJ; Ravanbod MR; Kalantarhormozi M; Nabipour I; Assadi M
Ann Endocrinol (Paris); 2023 Feb; 84(1):45-51. PubMed ID: 36126757
[TBL] [Abstract][Full Text] [Related]
5. Metastatic Medullary Thyroid Cancer: The Role of 68Gallium-DOTA-Somatostatin Analogue PET/CT and Peptide Receptor Radionuclide Therapy.
Hayes AR; Crawford A; Al Riyami K; Tang C; Bomanji J; Baldeweg SE; Wild D; Morganstein D; Harry A; Grozinsky-Glasberg S; Oleinikov K; Khoo B; Caplin ME; Nicolas GP; Grossman AB
J Clin Endocrinol Metab; 2021 Nov; 106(12):e4903-e4916. PubMed ID: 34379772
[TBL] [Abstract][Full Text] [Related]
6. Pancreatic imaging in MEN1-comparison of conventional and somatostatin receptor positron emission tomography/computed tomography imaging in real-life setting.
Kostiainen I; Majala S; Schildt J; Parviainen H; Kauhanen S; Seppänen H; Miettinen PJ; Matikainen N; Ryhänen EM; Schalin-Jäntti C
Eur J Endocrinol; 2023 May; 188(5):421-429. PubMed ID: 36943311
[TBL] [Abstract][Full Text] [Related]
7. [Theranostics and hybrid imaging for somatostatin receptor-expressing tumors].
Werner RA; Bengel FM; Derlin T
Radiologe; 2020 May; 60(5):413-420. PubMed ID: 32052116
[TBL] [Abstract][Full Text] [Related]
8. Clinical impact of
Tuncel M; Kılıçkap S; Süslü N
Ann Nucl Med; 2020 Sep; 34(9):663-674. PubMed ID: 32602032
[TBL] [Abstract][Full Text] [Related]
9. Medullary thyroid carcinoma - PET/CT imaging with 68Ga-labelled gastrin and somatostatin analogues.
Kunikowska J; Ziemnicka K; Pawlak D; Ruchała M; Kolasa A; Janicka-Jedyńska M; Woźniak A; Mikołajczak R; Królicki L
Endokrynol Pol; 2016; 67(1):68-71. PubMed ID: 26884118
[TBL] [Abstract][Full Text] [Related]
10. Multiparametric PET imaging in thyroid malignancy characterizing tumour heterogeneity: somatostatin receptors and glucose metabolism.
Traub-Weidinger T; Putzer D; von Guggenberg E; Dobrozemsky G; Nilica B; Kendler D; Bale R; Virgolini IJ
Eur J Nucl Med Mol Imaging; 2015 Dec; 42(13):1995-2001. PubMed ID: 26173620
[TBL] [Abstract][Full Text] [Related]
11. Gallium-68 Dotatate PET/CT is superior to other imaging modalities in the detection of medullary carcinoma of the thyroid in the presence of high serum calcitonin.
Tran K; Khan S; Taghizadehasl M; Palazzo F; Frilling A; Todd JF; Al-Nahhas A
Hell J Nucl Med; 2015; 18(1):19-24. PubMed ID: 25679074
[TBL] [Abstract][Full Text] [Related]
12. Detection rate of somatostatin receptor PET in patients with recurrent medullary thyroid carcinoma: a systematic review and a meta-analysis.
Treglia G; Tamburello A; Giovanella L
Hormones (Athens); 2017 Oct; 16(4):362-372. PubMed ID: 29518756
[TBL] [Abstract][Full Text] [Related]
13. The Impact of Somatostatin Receptor-Directed PET/CT on the Management of Patients with Neuroendocrine Tumor: A Systematic Review and Meta-Analysis.
Barrio M; Czernin J; Fanti S; Ambrosini V; Binse I; Du L; Eiber M; Herrmann K; Fendler WP
J Nucl Med; 2017 May; 58(5):756-761. PubMed ID: 28082438
[TBL] [Abstract][Full Text] [Related]
14. Differentiated thyroid cancer: a new perspective with radiolabeled somatostatin analogues for imaging and treatment of patients.
Versari A; Sollini M; Frasoldati A; Fraternali A; Filice A; Froio A; Asti M; Fioroni F; Cremonini N; Putzer D; Erba PA
Thyroid; 2014 Apr; 24(4):715-26. PubMed ID: 24102584
[TBL] [Abstract][Full Text] [Related]
15. Comparison of 68Ga PET/CT to Other Imaging Studies in Medullary Thyroid Cancer: Superiority in Detecting Bone Metastases.
Castroneves LA; Coura Filho G; de Freitas RMC; Salles R; Moyses RA; Lopez RVM; Pereira MAA; Tavares MR; Jorge AAL; Buchpiguel CA; Hoff AO
J Clin Endocrinol Metab; 2018 Sep; 103(9):3250-3259. PubMed ID: 29846642
[TBL] [Abstract][Full Text] [Related]
16. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S
Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
[TBL] [Abstract][Full Text] [Related]
17. Predictive Value of
Werner RA; Schmid JS; Higuchi T; Javadi MS; Rowe SP; Märkl B; Aulmann C; Fassnacht M; Kroiss M; Reiners C; Buck AK; Kreissl MC; Lapa C
J Nucl Med; 2018 May; 59(5):756-761. PubMed ID: 29025983
[TBL] [Abstract][Full Text] [Related]
18. Cardiac metastases from neuroendocrine neoplasms: complementary role of SSTR PET/CT and cardiac MRI.
Arnfield EG; Tam L; Pattison DA; Younger J; Chikatamarla VA; Wyld D; Burge M; McCormack L; Ladwa R; Ramsay S
J Nucl Cardiol; 2023 Dec; 30(6):2676-2691. PubMed ID: 37587328
[TBL] [Abstract][Full Text] [Related]
19. Validation of the SSTR-RADS 1.0 for the structured interpretation of SSTR-PET/CT and treatment planning in neuroendocrine tumor (NET) patients.
Grawe F; Ebner R; Geyer T; Beyer L; Winkelmann M; Sheikh GT; Eschbach R; Schmid-Tannwald C; Cyran CC; Ricke J; Bartenstein P; Heimer MM; Faggioni L; Spitzweg C; Fabritius MP; Auernhammer CJ; Ruebenthaler J
Eur Radiol; 2023 May; 33(5):3416-3424. PubMed ID: 36964768
[TBL] [Abstract][Full Text] [Related]
20. Anti-carcinoembryonic antigen antibodies versus somatostatin analogs in the detection of metastatic medullary thyroid carcinoma: are carcinoembryonic antigen and somatostatin receptor expression prognostic factors?
Behr TM; Gratz S; Markus PM; Dunn RM; Hüfner M; Schauer A; Fischer M; Munz DL; Becker H; Becker W
Cancer; 1997 Dec; 80(12 Suppl):2436-57. PubMed ID: 9406695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
